

Liste der Publikationen:

1. Sarnighausen H-E, Dodt C, Pietrowsky R, Born J, Fehm HL; Bedeutung von Ceruletid für die Reizverarbeitung junger und alter Menschen. *FOCUS MUL* 1995; 12(2):74-79
2. Dodt C, Sarnighausen H-E, Mölle M, Pietrowsky R, Born J, Fehm H L; Effects of ceruletide on event related potential indicators of cognitive information processing in young and aged humans. *Experimental and Clinical Endocrinology & Diabetes* 1995; Vol. 103 (Suppl. 1) V22:33
3. Dodt C, Sarnighausen H-E, Pietrowsky R, Fehm H L, Born J; Ceruletide improves Event-Related Potential Indicators of Cognitive Processing in Young but not in Elderly Humans. *J Clin Psychopharmacology* 1996; 16(6):440-5
4. Gerdov C, Böck A, Sarnighausen H-E, Herkner K R; Line Immunobinding Assay (LIBA): Suchtest auf spezifische Impfantikörper bei Kindern mit Verdacht auf Immundefizienz. *Pädiatrie & Pädologie (Wien)* 1996; 31(3):73-77
5. Sarnighausen H-E, Schneider S, Beyer J; Das künstliche Pancreas - der Schlüssel zum „hypoglycemia unawareness syndrom“?. *Z Gastroenterol* 1998; 36:753
6. Sarnighausen H-E, Schneider S, Reisch S, Kann P, Küstner E, Lichtwald K, Beyer J; Erhöhte Hypoglykämie-induzierte Wachstumsfreisetzung bei Typ-I Diabetikern mit „hypoglycemia unawareness syndrom“. Freier Vortrag bei XXVII. Colloquium Endocrinologicum Südwestdeutscher Arbeitsgruppen 6.11.98, Günzburg
7. Sarnighausen H-E, Benz C, Eickenberg M, Bockemühl J, Tschäpe H, Riemann JF; Typhoid Fever due to Salmonella Kapemba infection in a healthy middle aged man. *J Clin Microbiol* 1999; 37(7):2381-2
8. Sarnighausen H-E, Sarnighausen W, Kann P, Beyer J; Beurteilungen nach dem Schwerbehindertengesetz bei Patienten mit Prolaktinom. *Der medizinische Sachverständige* 1999; 95(6):200-3
9. Sarnighausen H-E, Schneider S, Reisch S, Kann P, Küstner E, Lichtwald K, Beyer; Enhanced human growth hormone counterregulation in type I diabetes mellitus with hypoglycemia unawareness is independent of defective catecholamine counterregulation. *Experimental and Clinical Endocrinology & Diabetes* 1999; Vol. 107 (Suppl. 1) p063:64

10. Sarnighausen H-E, Schneider S, Reisch S, Kann P, Lichtwald K, Beyer J; Kompensation der defekten Katecholamingegenregulation durch Hypoglykämie-induzierte STH-Hypersekretion bei Typ-I Diabetikern mit „Hypoglycemia unawareness Syndrome“. *Diabetes und Stoffwechsel* 1999; Vol. 8 (Suppl. 1):77-78
11. Beyer J, Schneider S, Sarnighausen H-E, Burchert D, Kann P, Küstner E, Kunt T, Kern A; Diagnostic procedures for hypoglycemic unawareness in type 1 diabetic patients. *Diabetologia Polska*, 1999, Vol. 6, Suppl 1:40
12. Sarnighausen H-E, Goitom K, Pohlmann T, Engelbach M, Zwermann O, Kann P, Küstner E, Beyer J; Internistisch-chirurgische Differentialdiagnostik und -therapie des inzidentellen Appendixkarzinoids mit pathologischem Calcitonin bei einem 29-jährigen gesunden Mann. Chirurgisch-Endokrinologisches Symposium 10.-11.9.1999, Mainz. Poster P33.
13. Goitom K, Sarnighausen H-E, Pohlmann T, Otto M, Engelbach M, Zwermann O, Kann P, Küstner E, Lichtwald K, Walgenbach S, Schunk K, Beyer J; Stimulierbare Hypercalcitoninämie bei inzidentellem Appendixkarzinoid. Freier Vortrag bei XXVIII. Colloquium Endocrinologicum Südwestdeutscher Arbeitsgruppen am 5.11.99 in Heidelberg
14. Schneider S, Beyer J, Sarnighausen H-E, Burchert D, Kann P, Küstner E, Kunt T; Vergleich des Hypoglykämieempfindens und der hormonellen Gegenregulation während einer kontrollierten Hypoglykämie. *DMW* 2000; 125:177-181
15. Sarnighausen H-E, Goitom K, Engelbach M, Pohlmann T, Kann P, Lichtwald K, Beyer J. SEVERE IMMOBILIZING OSTEOPOROSIS AND CARBAMAZEPINE-INDUCED HYPERCORTISOLISM. *Osteoporosis international*, 2000, Vol. 11, Suppl 2:S144
16. Sarnighausen H-E. Sinnspruch zur ärztlichen Kunst. *Dt. Ärzteblatt* 2000; 97(26):A-1786
17. Sarnighausen H-E, Arnold JC. mediquiz Fall 2560. *DMW* 2001; 126(16):A359-60
18. Sarnighausen H-E. Evidenz für Hyperventilation bei erhöhtem Hirndruck. *Intensivmed* 2001, eingereicht
19. Sarnighausen H-E, Wiehle F, Beckwilm J, Schmidt H-W, Kupper W. Überlebter plötzlicher Herztod als Diabetes-mellitus-Typ-2-Erstmanifestation *Med Klin* 2006; 101: Abstract-Band (49), P0507

20. Sarnighausen H-E, Wiehle F, Beckwilm J, Lüdemann R, Schmidt H-W, Kupper W. Überlebter plötzlicher Herztod als Diabetes mellitus Typ 2 Erstmanifestation *Diabetologie* 2006; 1:S150-410
21. Sarnighausen H-E. Zentrale Rolle des Hausarztes bei der Prävention des Diabetes mellitus Typ 2, Vortrag Herbsttagung der DDG am 5.11.2009, Berlin
22. Sarnighausen H-E, Gärtner C. Liraglutide verbessert als ergänzende Therapie zur ICT mit Insulinpumpe die Blutzuckerkontrolle bei Typ 1 Diabetes (Fallbericht) *Diabetologie & Stoffwechsel* 2010; 5:S45
23. Sarnighausen H-E. Zentrale Rolle des Hausarztes bei der Diabetesprävention, *Journal of Clinical Endocrinology and Metabolism* 2010; 3 (2):26-29
24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (u.a. Sarnighausen, HE). Rivaroxaban versus warfarin in non-valvular atrial fibrillation. *N Engl J Med.* 2011 Sep 8;365(10):883-91. Epub 2011 Aug 10.
25. Sarnighausen H-E. Leitlinien- oder Erfahrungsmedizin?, *Der Allgemeinarzt* 2012; 8:66-67

26. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al. The Registry of the German Competence NETWORK on Atrial Fibrillation (u.a. Sarnighausen HE): patient characteristics and initial management. *Europace* 2009;11:423–34.
27. Düngen HD, et al.; CIBIS-ELD investigators (u.a. Sarnighausen HE); Titration to target dose of bisoprolol vs. Carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. *European Journal of Heart Failure* 2011; 13(6): 670-680.
28. Patel MR et al., for the ROCKET AF Investigators (u.a. Sarnighausen HE); Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *N Engl J Med* 2011;365:883-391
29. Kirchhof P et al: Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Investigators (u.a. Sarnighausen HE); *Lancet* 2012; 380(9838): 238-246
30. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Investigators (u.a. Sarnighausen HE); *Circ Arrhythm Electrophysiol.* 2012; 5:43-51.
31. Hankey GJ, et al.; ROCKET AF Steering Committee Investigators (u.a. Sarnighausen HE). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurol.* 2012 Apr;11(4):315-22.
32. Halperin JL, et al.; ROCKET AF Steering Committee and Investigators (u.a. Sarnighausen HE). Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation.* 2014 Jul 8;130(2):138-46.
33. Sarnighausen H-E; Einschnitte in der Lebensführung durch Diabetes mellitus in der Versorgungsmedizin-Verordnung. Der medizinische Sachverständige 2016; 112(4):151-5
34. McMurray JJV, et al.; ATMOSPHERE Committees Investigators (u.a. Sarnighausen HE); Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure 2016; *N Engl J Med* 2016; 374:1521-1532
35. Camm AJ, et al. on behalf of the XANTUS Investigators (u.a. Sarnighausen HE); XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation; *European Heart Journal* (2016) 37, 1145–1153.
36. Pokorney SD, et al.; ROCKET AF Steering Committee Investigators (u.a. Sarnighausen HE). Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients

With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. *J Am Heart Assoc.* 2016 Mar 8;5(3):e002197.

37. Kazda CM, et al.; Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. *Diabetes Care* 2016;39:1241-9 (Contribution as PI, Sarnighausen HE)
38. Ridker PM, et al.; CANTOS Trial Group (u.a. Sarnighausen HE); Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease; *N Engl J Med* 2017; 377:1119-1131
39. Carlos Arturo Areán Martínez, et al. on behalf of the XANTUS Investigators (u.a. Sarnighausen HE); XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. *The Egyptian Heart Journal* 70 (2018) 307–313
40. Solomon SD. Et al.; PARAGON-HF Investigators (u.a. Sarnighausen HE); Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction; *N Engl J Med* 2019; 381:1609-1620
41. Sarnighausen H-E, Sarnighausen H-U, Willner-Sarnighausen C; Monocentric randomised prospective intraindividual parallel group comparison study to calculate hbA1c from self-monitored blood glucose values using a special diary with biofeedback system. *European Journal of Preventive Cardiology*, vol. 27, 1_suppl: P235, First Published July 29, 2020
42. Packer M, et al. for the EMPEROR-Reduced Trial Investigators (u.a. Sarnighausen HE, Praxis Oedeme) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med* 2020; 383(15):1413–24
43. Kirchhof P et al. for the EAST-AFNET 4 Trial Investigators (u.a. Sarnighausen HE, Praxis Oedeme) Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *N Engl J Med* 2020; 383:1305-16.
44. Pieske B et al. on behalf of the PARALLAX Investigators (u.a. Sarnighausen HE, Praxis Oedeme) Angiotensin receptor neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction – the PARALLAX trial. ESC Virtual Congress 2020 – Clinical Trials Hotline Session Aug 30 2020
45. Paulus Kirchhof, et al. on behalf of the XANTUS Investigators* (u.a. Sarnighausen HE, Praxis Oedeme); Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. *J Am Heart Assoc.* 2020;9: e009530.

46. Camm AJ, et al. on behalf of the XANTUS Investigators (u.a. Sarnighausen HE); Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. *Clin Cardiol.* 2020;43:1405–1413.
47. Packer M, Anker SD, Butler J, et al. For the EMPEROR-Reduced Trial Committees and Investigators (u.a. Sarnighausen HE). Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial. *Eur Heart J* 2021; 42(6):671–80.
48. Packer M, Anker SD, Butler J, et al. For the EMPEROR-Reduced Trial Committees and Investigators (u.a. Sarnighausen HE). Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. *Circulation* 2021; 143(4):326–36.
49. Anker SD, Butler J, Filippatos G, et al. On behalf of the EMPEROR-Reduced Trial Committees and Investigators (u.a. Sarnighausen HE). Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. *Circulation* 2021; 143(4):337–49.
50. Sarnighausen H-E, Kseibi S, Baumbach C, Willner-Sarnighausen C. Secondary prophylaxis after cardiogenic shock in a 47-years old man presenting with STEMI with positive family history for sudden cardiac death (father) and very high Lp(a) as single cardiovascular risk factor. Clinical Case HFA Congress 2021, published
51. Sarnighausen H-E, Gaertner L-S, Willner-Sarnighausen C. Immediate implementation of three 2019 european society of cardiology guidelines in daily practice. *Eur Heart J* 2021, Vol 42, Issue Suppl_1, ehab724.2557
52. Anker S.D., Butler J., et al. for the EMPEROR-Preserved Trial Investigators (u.a. Sarnighausen HE, Praxis Oedeme). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med* 2021;385:1451-61.
53. Packer M. et al. for the EMPEROR-Preserved Trial Study Group (u.a. Sarnighausen HE, Praxis Oedeme). Empagliflozin on Worsening Heart Failure Events in in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. *Circulation.* 2021;144:1284–1294.
54. Packer M. et al. for the EMPEROR Study Group (u.a. Sarnighausen HE, Praxis Oedeme). Empagliflozin and Major Renal Outcomes in Heart Failure. *N Engl J Med* 2021;385:1531-33.
55. M. Böhm, et al., on behalf of the EMPEROR-Reduced Investigators (u.a. Sarnighausen HE), Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. *J Am Coll Cardiol*; 2021 Sep 28; 78 (13)1337-1348

56. M. Nabauer, et al.; on behalf of the AFNETregistry investigators (u.a. Sarnighausen HE), Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETWORK (AFNET). *Europace* (2021) 23, 1903–1912.
57. Rillig A, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. *Circulation* 2021; 144:845-58. (Contribution as PI in EAST AFNET 4, Sarnighausen HE)
58. Pieske B, et al.; PARALLAX Investigators (u.a. Sarnighausen HE) and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. *JAMA*. 2021 Nov 16;326(19):1919-1929.
59. Verma S, et al.; EMPEROR-Reduced trial committees and investigators (e.g. Sarnighausen HE). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. *Lancet Diabetes Endocrinol*. 2022 Jan;10(1):35-45.
60. Metzner A, et al.; Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST – AFNET 4 trial. *Europace* (2022) 24, 552-64 (Contribution as PI, Sarnighausen HE)
61. Willems S, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. *Eur Heart J* (2022) 43, 1219-30 (Contribution as PI, Sarnighausen HE)
62. J. Butler et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation* 2022; 146:184-193 (Contribution as PI, Sarnighausen HE)
63. AM. Jackson, JJV. McMurray et al., on behalf of the PARAGON-HF Committees and Investigators (e.g. Sarnighausen HE), Diabetes and Pre-diabetes in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail* (2022) doi:10.1002/ejhf.2403
64. Sarnighausen HE. Die Echokardiographie als Schlüsseltechnologie in der primärärztlichen Versorgung: Anregung zur Vorbereitung einer Antragsvorlage „Anlage Herzinsuffizienz“ nach der ASV-Richtlinie beim GbA“ Vortrag im Rahmen der 88. Jahrestagung der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. Mannheim, 20.04.2022 in der Sitzung Praktische Umsetzung der Herzinsuffizienztherapie in der ambulanten Versorgung
65. G. Filippatos, et al. on behalf of the EMPEROR-Preserved Trial Committees and Investigators (e.g. Sarnighausen HE). Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. *Circulation* (2022)146: 28 Jun 2022
66. A. Peikert, et al. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction:

insights from PARAGON-HF. *Eur J Heart Fail* 2022; 24:794-803 (Contribution as PI, Sarnighausen HE)

67. A. Goette, et al. on behalf of the EAST-Investigators (e.g. Sarnighausen HE), Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. *JACC* (2022) 80:283 – 295
68. Sarnighausen H-E, Willner-Sarnighausen C. May oral anticoagulation be considered for secondary prevention after coronary artery bypass operation complicated with postoperative atrial fibrillation in a high-risk patient? Clinical Case, ESC Congress 26 AUG 2022, Barcelona
69. Steven E Nissen, et al. For the Lp(a)HERITAGE Investigators (e.g. Sarnighausen HE). Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. *Open Heart* 2022;9:e002060. doi:10.1136/openhrt-2022-002060